Unlock instant, AI-driven research and patent intelligence for your innovation.

Ipragliflozin new crystal form

A technology of crystal form and angle, applied in the field of new crystal forms of Ipagliflozin, can solve problems such as affecting drug safety

Inactive Publication Date: 2018-02-16
WEIHAI GUANBIAO INFORMATION TECH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The test found that the raw material medicine of Ipagliflozin prepared by the prior art belongs to the amorphous powder. During

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ipragliflozin new crystal form

Examples

Experimental program
Comparison scheme
Effect test
No Example Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a new crystal form of ipagliflozin, which belongs to the technical field of raw material medicine preparation. The technical scheme of the present invention is: a new crystal form of Ipagliflozin L-proline, in the powder X-ray diffraction pattern represented by 2θ angle, at 13.86, 14.62, 16.21, 18.74, 19.68, 20.78, 22.09 , 23.10, 24.08, 26.24, 27.35, 29.24, 29.48, 30.21, 32.18, 32.78 have strong absorption peaks. The invention provides a stable new crystal form of ipagliflozin.

Description

technical field [0001] The invention relates to a new crystal form of ipagliflozin, which belongs to the technical field of raw material medicine preparation. Background technique [0002] Ipagliflozin, whose English name is ipragliflozin, was approved for marketing in Japan in January 2014. The original research company is Astellas Japan. Belonging to selective sodium / sodium-glucose transporter 2 (SGLT2) inhibitors, the drug inhibits glucose reuptake by selectively inhibiting SGLT2, thereby lowering blood sugar. A Phase III pivotal trial of Ipagliflozin monotherapy and multiple clinical studies of the drug in combination with other hypoglycemic drugs supported the approval of this product in Japan. This medicine is made and sold by Astellas Corporation. [0003] The test found that the raw material medicine of Ipagliflozin prepared by the prior art belongs to the amorphous powder, and during the storage of the amorphous powder, as time goes by, the related substances ten...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D409/10C07D207/16
CPCC07D409/10C07B2200/13C07D207/16
Inventor 孙爱梅
Owner WEIHAI GUANBIAO INFORMATION TECH